SCHEMBL2086757

SCHEMBL2086757

Cc1ccccc1C(=O)c1cn2cc(Cl)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.52
KDM4E B2RXH2 4/20 0.52
HRH4 Q9H3N8 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
NPC1 O15118 3/20 0.46
ELANE P08246 1/20 0.44
ESRRA P11474 1/20 0.43
TP53 P04637 1/20 0.43
GFER P55789 1/20 0.41
ALDH1A1 P00352 2/20 0.41
ENPP3 O14638 1/20 0.41
ALPL P05186 1/20 0.41
XIAP P98170 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.40
APP P05067 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
MAP3K5 Q99683 1/20 0.40
CLK1 P49759 1/20 0.40
DYRK1A Q13627 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4211423 0.80 RAB9A (0.53) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL2086752 0.79 HRH4 (0.54) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL2087963 0.77 HRH4 (0.50) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL4213158 0.77 HRH4 (0.55) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL3663129 0.77 HRH4 (0.49) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL20646875 0.76 HRH4 (0.61) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL299158 0.75 HRH4 (0.58) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL4242240 0.74 EGLN1 (0.53) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL4220034 0.73 HRH4 (0.48) RAB9AKDM4EHRH4HRH3NPC1
SCHEMBL741904 0.73 KDM4E (0.64) RAB9AKDM4EHRH4HRH3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US claimed
US-7902219-B2 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-08 US disclosed
EP-2040703-B1 DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-21 EP disclosed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF NR4A2, NR4A3, NCOR1 RAB9A 3310/4885KDM4E 2764/4885HRH4 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.